Relative to its peers, RNN does not have very much institutional sponsorship. The 2.53% of shares outstanding held by institutional investors is among the least of any stock in the Biotechnology industry.
| Mutual fund holders | 3.18% |
| Individual stakeholders | 16.58% |
| Other institutional | -0.65% |